This webinar described a new service to be introduced by IQVIA to promote the prescribing of digital therapeutic apps in secondary care, and the consequent gathering of evidence of efficacy.
The use of real world evidence (RWE) to support market access decisions, reimbursement strategies, and comparative effectiveness has become increasingly imperative and far-reaching in the past few years. Various data assets, such as app utilisation, patient recorded data and electronic health records, appropriately anonymised, provide a rich source in support of clinical evidence development across the medical technology industry.
During this webinar, experts from IQVIA highlighted:
- RWE strategies that can be used to support development needs in MedTech, including research initiatives, market development, and reimbursement planning, using comparative effectiveness analyses.
- How rich data sources used in RWE studies can be leveraged to support clinical evidence requirements.
- How linked/integrated data sources provide options to support evidence development requirements.
- How RWE is being used for regulatory decision-making in MedTech, and what is needed for success.
